Blue Jet Healthcare Limited
₹504.40+₹0.55 (+0.1%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹8,659 Cr
- P/E
- 24.6x
- EV / EBITDA
- 34.4x
- Revenue
- ₹1,030 Cr
- Net margin
- 23.0%
- ROCE
- 27.2%
Price chart
Technical chartScreen technicals →-22.1% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -6.4%
- 3M
- -17.7%
- 6M
- +13.7%
- 1Y
- -22.1%
- 5Y
- +29.1%
52-week range
Day change +₹0.55 (+0.1%) from ₹504 to ₹504 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in BLUEJET, bought on each weekday since 2023.
AI Summary
Indian StockStrengths1
- Healthy return on equity of 19.4%
Concerns0
Rule-based from financial data. Not advice.
About the company
Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products.
Read moreShow less
Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products. It provides contrast media intermediates; niche pharmaceutical intermediates and APIs; and CDMO/CMO services, as well as end-to-end solutions from process development and commercialization of NCEs, advance intermediates, API, and building blocks. The company develops, manufactures, and markets saccharin and related salts. It has operations in India, Norway, France, the United States, Italy, Sweden, and internationally. Blue Jet Healthcare Limited was incorporated in 1968 and is headquartered in Thane, India.
- Sector
- Healthcare
- Shares outstanding
- 17.4 Cr shares
- ISIN
- INE0KBH01020
- BSE code
- 544009
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹8,659 Cr
- P/E
- 24.6x
- P/B
- 6.9x
- EV / EBITDA
- 34.4x
- EV / Sales
- 12.0x
- P/S
- 12.2x
- Earnings yield
- 4.1%
- 52-week high
- ₹674.75
- 52-week low
- ₹327.25
Profitability
- Operating margin
- 32.4%
- Net margin
- 23.0%
- EBITDA margin
- 35.0%
- ROE
- 19.4%
- ROCE
- 27.2%
- ROA
- 15.5%
- Dividend payout
- 11.0%
- Tax rate
- 26.0%
- Other income, % of PBT
- 8.2%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1,030 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 44.7%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 5.8%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹249 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 2.5%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 86.0%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 2.5%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹241 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 69.7%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹8.00 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 22.9%
Solvency and efficiency
- Current ratio
- 3.50
- Debt / Equity
- 0.00
- Debt / Assets
- 0.00
- Debt / EBITDA
- 0.01
- Financial leverage
- 1.25
- CFO / Net profit
- 1.47
- Cash / Market cap
- 5.6%
- Cash per share
- ₹28.18
- Asset turnover
- 0.67
- Fixed asset turnover
- 4.14
- Capital intensity
- 0.24
- Debtor days
- 91 days
- Inventory turnover
- 2.42
- Cash conversion cycle
- 206 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹30 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹652 Cr |
| Sales | Operating profit | ₹378 Cr |
| Operating profit | Depreciation | ₹18 Cr |
| Operating profit | Profit before tax | ₹360 Cr |
| Other income | Profit before tax | ₹46 Cr |
| Profit before tax | Tax and other | ₹101 Cr |
| Profit before tax | Net profit | ₹305 Cr |
Revenue and net profit
Revenue grew 44.7% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹499 Cr | ₹142 Cr |
| FY2022 | ₹683 Cr | ₹182 Cr |
| FY2023 | ₹721 Cr | ₹160 Cr |
| FY2024 | ₹712 Cr | ₹164 Cr |
| FY2025 | ₹1,030 Cr | ₹305 Cr |
Cash flows
FY2025: ₹46.0 Cr from operations, ₹11.0 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹137 Cr | ₹76 Cr |
| FY2022 | ₹146 Cr | ₹70 Cr |
| FY2023 | ₹142 Cr | -₹5 Cr |
| FY2024 | ₹241 Cr | -₹23 Cr |
| FY2025 | ₹46 Cr | ₹11 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹1,030 Cr+44.7%1Y
- Net profit
- ₹305 Cr+86.0%1Y
- Cash from operations
- ₹46 Cr
- Free cash flow
- ₹11 Cr
- Revenue CAGR, 5Y
- 5.8%
- EBITDA CAGR, 5Y
- 2.5%
- Net profit CAGR, 5Y
- 2.5%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹1,030 Cr | ₹378 Cr | — | ₹305 Cr | ₹46 Cr | ₹11 Cr | 26.9% | +44.7% | +86.0% |
Monthly returns
Month-by-month returns of BLUEJET across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹1,418 Cr |
| Equity capital | ₹35 Cr |
| Reserves | ₹1,098 Cr |
| Borrowings | ₹21 Cr |
| Other liabilities | ₹263 Cr |
| Assets | ₹1,418 Cr |
| Fixed assets | ₹300 Cr |
| Capital work in progress | ₹89 Cr |
| Investments | ₹187 Cr |
| Other assets | ₹841 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
BLUEJET trades at 24.6x earnings against a peer median of 52.6x (a 53% discount).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Blue Jet Healthcare LimitedBLUEJETthis companyP/E ↓ discount | ₹8,659 Cr | 24.6x | 6.9x | 19.4% | 34.4x |
| HealthCare Global Enterprises LimitedHCG | ₹9,408 Cr | 513.0x | 8.0x | 2.8% | 49.9x |
| Sanofi India LtdSANOFI | ₹9,387 Cr | 25.4x | 12.0x | — | — |
| Jeena Sikho Lifecare LimitedJSLL | ₹8,968 Cr | 58.2x | 25.2x | 35.9% | 90.3x |
| PROCTER & GAMBLE HEALTH LIMITEDPGHL | ₹8,946 Cr | 29.2x | 14.4x | — | — |
| Jupiter Life Line Hospitals LimitedJLHL | ₹8,877 Cr | 46.3x | 5.9x | 12.2% | 34.5x |
| Corona Remedies LimitedCORONA | ₹8,749 Cr | 55.1x | — | 18.8% | 55.0x |
| STRIDES PHARMA SCIENCE LIMITEDSTAR | ₹8,552 Cr | 112.0x | 2.7x | 1.3% | 35.5x |
| Sequent Scientific LimitedVIYASH | ₹8,288 Cr | 531.0x | 4.1x | 0.1% | 633.5x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
BLUEJET since 1 January, against earlier years.
Historical volatility
BLUEJET's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 41.0% |
| FY2022 | 36.0% |
| FY2023 | 30.0% |
| FY2024 | 32.0% |
| FY2025 | 37.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹1,030 Cr |
| Costs | |
| Interest | ₹0 Cr |
| Expenses | ₹652 Cr |
| Operating profitOperating Profit | ₹378 Cr |
| Other income and charges | |
| Profit before tax | ₹406 Cr |
| Tax | |
| Net profitNet Profit | ₹305 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹1,418 Cr |
| Equity capitalEquity Capital | ₹35 Cr |
| Reserves | ₹1,098 Cr |
| Borrowings | ₹21 Cr |
| Other liabilitiesOther Liabilities | ₹263 Cr |
| AssetsTotal Assets | ₹1,418 Cr |
| Fixed assetsFixed Assets | ₹300 Cr |
| Capital work in progressCWIP | ₹89 Cr |
| Investments | ₹187 Cr |
| Other assetsOther Assets | ₹841 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹46 Cr |
| Investing cash flowCash from Investing Activity | -₹35 Cr |
| Financing cash flowCash from Financing Activity | -₹19 Cr |
| Change in cashNet Cash Flow | -₹8 Cr |
Learn while you research
Academy chapters picked for Blue Jet Healthcare Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Growth Investing45% revenue growth is in the top tier, learn how to value growth.7 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read